

lipase, blood glucose, plasma hepatitis C RNA, pregnancy test, serum cholesterol, serum lipids, hepatitis serology, baseline and periodically

- Renal tests: urinalysis, protein, blood, serum creatinine

- Lipoatrophy/lipodystrophy during treatment

- Bowel pattern before, during treatment

- Weakness, tremors, confusion, dizziness; product may have to be decreased, discontinued

- Viral load, CD4 counts, plasma HIV RNA at baseline and throughout treatment

- **Peripheral neuropathy:** tingling, pain in extremities; discontinue product, may not resolve after treatment is discontinued

- **Pregnancy/breastfeeding:** use only if benefits outweigh fetal risk; register patient in the Antiretroviral Pregnancy Registry, 1-800-258-4263; do not breastfeed

#### Evaluate:

- Therapeutic response: decreased symptoms of HIV

#### Teach patient/family:

- **About the signs of peripheral neuropathy:** burning, weakness, pain, prickling feeling in extremities

- That product should not be given with antineoplastics

- That product is not a cure for AIDS but will control symptoms

- To notify prescriber if sore throat, swollen lymph nodes, malaise, fever occur; that other products may be needed to prevent other infections

- That, even with use of product, patient may pass AIDS virus to others

- That follow-up visits are necessary; that serious toxicity may occur; that blood counts must be done q2wk

- **That serious product interactions may occur if other medications are ingested; to see prescriber before taking chloramphenicol, dapsone, CISplatin, didanosine, ethambutol, lithium, antifungals, antineoplastics**

- **To notify prescriber if pregnancy is planned or suspected; that fatal lactic acidosis may occur; to avoid breastfeeding**

- That product may cause fainting or dizziness

## stiripentol

(stir-i-pen' tol)

### Diacomit

*Func. class.:* Anticonvulsant—miscellaneous

**ACTION:** Several possible mechanisms of action, including effects on the gamma-aminobutyric acid (GABA) A receptor and novel inhibition of lactate dehydrogenase

**USES:** Seizures associated with Dravet syndrome in patients taking clobazam

**CONTRAINDICATIONS:** Hypersensitivity

**Precautions:** Abrupt discontinuation, breastfeeding, children, depression, driving or operating machinery, growth inhibition, hepatic disease, neutropenia, PKU, pregnancy, renal disease, suicidal ideation, thrombocytopenia

## DOSAGE AND ROUTES

- **Adult/adolescent/child 12-17 yr: PO** 50 mg/kg/day in 2 or 3 divided doses; round to nearest possible dosage, which is usually within 50 to 150 mg of the recommended 50 mg/kg/day. Max 3000 mg/day

**Available forms:** Caps 250, 500 mg

#### Administer:

- Use seizure precautions
- Give during a meal, swallow whole with glass of water; do not break or open capsules
- Take missed doses as soon as possible; if it is almost time for the next dose, take only that dose, do not take double doses

## SIDE EFFECTS

**CNS:** Suicidal ideation, depression, drowsiness, dizziness, ataxia, tremor, agitation, fatigue, insomnia, fever

**GI:** Anorexia, weight loss or gain, nausea, vomiting

**HEMA:** Neutropenia, thrombocytopenia

**MISC:** Infection, hypersalivation

S